Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
Hepatology
    September 2025
  1. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
    One step closer to a pan-genotypic hepatitis C vaccine.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001530.
    >> Share

  2. ZHANG F, Zhao Y, Bian L, Wang X, et al
    IL1beta Signaling Mediates the Interaction Between Hepatitis B and C Viruses.
    Hepatology. 2025 Sep 12. doi: 10.1097/HEP.0000000000001525.
    >> Share

  3. DASARATHY S, Tu W, Welch N, Gawrieh S, et al
    Natural history and development of a novel composite endpoint in patients with alcohol-associated Hepatitis: Data from a prospective multicenter study.
    Hepatology. 2025 Sep 9. doi: 10.1097/HEP.0000000000001513.
    >> Share

  4. URBANEK-QUAING M, Chou YH, Gupta MK, Steppich K, et al
    Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition.
    Hepatology. 2025;82:739-754.
    >> Share

    August 2025
  5. GAO P, Ge W, Wang R
    Letter to the editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis.
    Hepatology. 2025 Aug 4. doi: 10.1097/HEP.0000000000001485.
    >> Share

    July 2025
  6. CHOI WM, Seto WK
    Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001469.
    >> Share

    June 2025
  7. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    >> Share

  8. GOMEZ-MORENO A, Bradley D, Ploss A
    Building hepatitis B virus gene transcription from the bottom up.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001437.
    >> Share

  9. WANG H, Wang S, Lei Y, Chen Y, et al
    Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
    >> Share

  10. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    >> Share

  11. OZMERT EH
    Infliximab to the rescue: Autoimmune hepatitis meets its match.
    Hepatology. 2025;81:1621-1622.
    >> Share

    May 2025
  12. KILANY MM, Sonneveld MJ, Feld JJ, Janssen HLA, et al
    Management of Immune Tolerant Chronic Hepatitis B.
    Hepatology. 2025 May 20. doi: 10.1097/HEP.0000000000001407.
    >> Share

    April 2025
  13. WANG J, Zhang S, Fan T, Wu C, et al
    Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
    >> Share

  14. TSENG TC, Kao JH
    Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
    >> Share

  15. TSENG TC, Lok AS
    Accurate identification and risk-stratification of HBeAg-negative indeterminate phase of chronic hepatitis B: not all shades of grey are the same.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001353.
    >> Share

  16. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
    >> Share

    March 2025
  17. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    >> Share

  18. SU R, Tao X, Yan L, Liu Y, et al
    Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
    >> Share

  19. TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
    Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
    >> Share

  20. ZHANG T, Huang CJ, Chen HT, Huang YH, et al
    HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
    Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
    >> Share

    February 2025
  21. SNIJDERS RJALM, Janik MK, Mund M, Uhlenbusch N, et al
    Health-related quality of life is impaired in people with autoimmune hepatitis: Results of a multicentre cross-sectional study within the European Reference Network.
    Hepatology. 2025 Feb 19. doi: 10.1097/HEP.0000000000001271.
    >> Share

  22. WONG GL, Chan HL
    Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
    Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
    >> Share

  23. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2025;81:609-624.
    >> Share

  24. WEDEMEYER H, Leus M, Battersby TR, Glenn J, et al
    HDV RNA assays: Performance characteristics, clinical utility, and challenges.
    Hepatology. 2025;81:637-650.
    >> Share

    January 2025
  25. SHI MA, Pungwe P, Comer LL, Balakrishnan M, et al
    Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials.
    Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001237.
    >> Share

  26. CHEN PC, Deterding K, Engelskircher SA, Port K, et al
    TIGIT-expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.
    Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001238.
    >> Share

  27. NISHITSUJI H, Naito Y, Murakami Y, Sugiyama M, et al
    Identification of glycogen synthase kinase 3alpha/beta as a host factor required for hepatitis B virus transcription using high-throughput screening.
    Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.
    >> Share

  28. PATEL K, Asrani SK, Fiel MI, Levine D, et al
    Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:358-379.
    >> Share

    December 2024
  29. CHEN KQ, Chen Y, Peng JF, Tang WR, et al
    Letter to the Editor: Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001210.
    >> Share

  30. BERETTA M, Vesin B, Wei Y, Planchais C, et al
    Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001179.
    >> Share

  31. MULLISH BH, Thursz MR
    Alcohol-associated liver disease: Emerging therapeutic strategies.
    Hepatology. 2024;80:1372-1389.
    >> Share

    November 2024
  32. JOHN BV, Bastaich D, Dahman B
    Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
    >> Share

  33. HE Z, Wang C, Tian H
    Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
    >> Share


  34. Erratum: Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose.
    Hepatology. 2024;80:E90.
    >> Share


  35. Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.
    Hepatology. 2024;80:E86.
    >> Share

  36. CHUNG Y, IIkay E, Heneghan MA
    Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol.
    Hepatology. 2024;80:1000-1002.
    >> Share

  37. KEZER CA
    The ultimate ensemble: Seeing the forest through the trees in alcohol-associated hepatitis.
    Hepatology. 2024;80:995-996.
    >> Share

  38. MALHI G, Arab JP
    Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol.
    Hepatology. 2024;80:989-990.
    >> Share

    October 2024
  39. JOHN BV, Bastaich D, Dahman B
    Reply: Association of hepatitis D virus infection with liver-related outcomes.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001142.
    >> Share

  40. LUO C
    Letter to the Editor: Association of hepatitis D virus infection with liver-related outcomes.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001140.
    >> Share

  41. WRANKE A, Wedemeyer H
    Hepatitis D virus - still the devil !
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001144.
    >> Share

  42. COLPITTS CC, Baumert TF
    Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions.
    Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132.
    >> Share

  43. OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al
    Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114.
    >> Share

  44. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events.
    Hepatology. 2024;80:E50-E52.
    >> Share

  45. LI Z, Zhang Y, Li Y, Lan J, et al
    Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events.
    Hepatology. 2024;80:E48-E49.
    >> Share

  46. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    >> Share

    September 2024
  47. HSU CL, Wang L, Maestri E, Jacob AR, et al
    Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
    Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046.
    >> Share

  48. SONG M, Wang H, Tian X, Gao J, et al
    TIPE2 protein restrains invariant NKT activation and protects against immune-mediated hepatitis in mice.
    Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001104.
    >> Share

  49. LIAW YF, Papatheodoridis G
    Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift.
    Hepatology. 2024 Sep 24. doi: 10.1097/HEP.0000000000001107.
    >> Share

  50. ZHU J, Wu R, Yang T, Yuan Y, et al
    Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery.
    Hepatology. 2024 Sep 20. doi: 10.1097/HEP.0000000000001101.
    >> Share

  51. LYU X, Sze KM, Lee JM, Husain A, et al
    Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
    Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
    >> Share

  52. JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
    Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
    >> Share

  53. EFE C, Lytvyak E, Eskazan T, Liberal R, et al
    Efficacy and safety of infliximab in patients with autoimmune hepatitis.
    Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001089.
    >> Share

  54. SUN B, da Costa KAS, Alrubayyi A, Kokici J, et al
    HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses.
    Hepatology. 2024;80:649-663.
    >> Share

  55. LI Z, Zhang Y, Li Y, Chen X, et al
    Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
    Hepatology. 2024;80:E37-E38.
    >> Share

  56. HUANG DQ, Nguyen MH
    Reply: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
    Hepatology. 2024;80:E39.
    >> Share

    August 2024
  57. ABRAVANEL F, Vignon C, Mercier A, Gaumery JB, et al
    Large-scale hepatitis E virus genotype 3 outbreak on new caledonia island.
    Hepatology. 2024 Aug 30. doi: 10.1097/HEP.0000000000001081.
    >> Share

  58. MCGETTIGAN BM, Osna N
    Functional humoral immunity is crucial to outcomes in severe alcohol-associated hepatitis.
    Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001079.
    >> Share

  59. KHANAM A, Kottilil S
    Reversal of immune exhaustion for functional cure of chronic hepatitis B: Is the time right?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001059.
    >> Share

  60. VAN DER MEER AJ, Sonneveld MJ
    Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
    >> Share

  61. STAFYLIS C, Vij AP, Klausner JD
    Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and treatment to achieve elimination in the united states.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051.
    >> Share

  62. GRATACOS-GINES J, Ventura-Cots M, Pose E
    Reply: Don't forget to discuss TIPS in patients surviving an episode of alcoholic hepatitis.
    Hepatology. 2024 Aug 2. doi: 10.1097/HEP.0000000000001040.
    >> Share

    July 2024
  63. RUDLER M, Bouzbib C, Thabut D
    To the Editor: Don't forget to discuss TIPS in patients surviving an episode of alcoholic hepatitis.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001038.
    >> Share

  64. YUAN Q, Hodgkinson C, Liu X, Barton B, et al
    Exome-wide association analysis identifies novel risk loci for alcohol-associated hepatitis.
    Hepatology. 2024 Jul 26. doi: 10.1097/HEP.0000000000001027.
    >> Share

  65. PATIDAR KR, Tu W, Cotter TG, Simonetto DA, et al
    Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001019.
    >> Share

  66. QIAN J, Xie Y, Mao Q, Xie Q, et al
    A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001006.
    >> Share

  67. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005.
    >> Share


  68. Erratum: The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
    Hepatology. 2024;80:E22.
    >> Share


  69. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    >> Share

    June 2024
  70. LAW JL, Drummer HE
    Bridging the gap: A new tool to down select HCV vaccine candidates.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
    >> Share

  71. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    >> Share

  72. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    >> Share

  73. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    >> Share

  74. BITTERMANN T, Yagan L, Kathawate RG, Weinberg EM, et al
    Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis.
    Hepatology. 2024 Jun 12. doi: 10.1097/HEP.0000000000000961.
    >> Share

  75. TANG T, Li LQ, Wang ZD
    Baseline viral load in chronic hepatitis B may be clinically significant but must be interpreted with caution.
    Hepatology. 2024 Jun 6. doi: 10.1097/HEP.0000000000000956.
    >> Share

  76. CORNBERG M, Wedemeyer H
    Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
    Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
    >> Share

  77. HOWELL J, Hellard ME
    Reply: Provider preparedness for functional cure of chronic hepatitis B.
    Hepatology. 2024;79:E160.
    >> Share

    May 2024
  78. WELTZSCH JP, Bartel CF, Waldmann M, Renne T, et al
    Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000940.
    >> Share

  79. LIAO X, Fan R
    Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000942.
    >> Share

  80. FENG Z
    Cathepsins prime hepatitis E virus for cell entry.
    Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000936.
    >> Share

  81. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    >> Share

  82. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    >> Share

  83. LUO C
    Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000928.
    >> Share

  84. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
    Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
    >> Share

  85. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    >> Share

  86. KLOHN M, Burkard T, Janzen J, Haase JA, et al
    Targeting cellular cathepsins inhibits hepatitis E virus entry.
    Hepatology. 2024 May 10. doi: 10.1097/HEP.0000000000000912.
    >> Share

  87. SHENOY A, Fontana RJ
    HDV screening in chronic HBV: An unmet need of growing importance.
    Hepatology. 2024;79:979-982.
    >> Share

  88. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    >> Share

    April 2024
  89. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    >> Share

  90. ZAHOOR MA, Feld JB, Lin HS, Mosa AI, et al
    Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000878.
    >> Share

  91. DUNN W, Li Y, Singal AK, Simonetto DA, et al
    An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000883.
    >> Share

  92. CHOI WM, Lim YS
    "Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients".
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000884.
    >> Share

  93. HE T, Zhang D
    Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000882.
    >> Share

    March 2024
  94. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
    NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
    >> Share

  95. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    >> Share

  96. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    >> Share

  97. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  98. PERRILLO RP, Janssen HLA
    Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000810.
    >> Share

  99. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    >> Share

  100. GRATACOS-GINES J, Ruz-Zafra P, Celada-Sendino M, Marti-Carretero A, et al
    Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000825.
    >> Share

    February 2024
  101. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  102. YAMAZAKI T, Kouno T, Hsu CL, Hartmann P, et al
    Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000777.
    >> Share

  103. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    >> Share

  104. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  105. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    >> Share

  106. DIMOU A, Zachou K, Kostara C, Azariadis K, et al
    NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis.
    Hepatology. 2024 Feb 5. doi: 10.1097/HEP.0000000000000767.
    >> Share

    January 2024
  107. CHOI WM, Yip TC, Kim WR, Yee LJ, et al
    Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752.
    >> Share


  108. Erratum: Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
    Hepatology. 2024 Jan 19. doi: 10.1097/HEP.0000000000000759.
    >> Share

  109. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    >> Share

  110. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    >> Share

    December 2023
  111. KINAST V, Todt D
    The relation of host genetics and symptomatic hepatitis E.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000749.
    >> Share

  112. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    >> Share

  113. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    >> Share

  114. YIP TC, Brunetto MR
    Hepatitis B surface antigen seroclearance is uncommon but durable in the long run.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000741.
    >> Share

  115. SAADAT A, Gouttenoire J, Ripellino P, Semela D, et al
    Inborn errors of type I interferon immunity in patients with symptomatic acute hepatitis E.
    Hepatology. 2023 Dec 8. doi: 10.1097/HEP.0000000000000701.
    >> Share

    November 2023
  116. SHEN J, Zhang K, Liu M, Wang T, et al
    Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000682.
    >> Share

  117. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    >> Share

  118. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
    Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
    >> Share

  119. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    >> Share

  120. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    >> Share

  121. DE CARVALHO RIBEIRO M, Babuta M, Szabo G
    Reply: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000686.
    >> Share

  122. BRUDEN D, McMahon BJ, Snowball M, Towshend-Bulson L, et al
    Rate and durability of clearance of hepatitis B surface antigen in Alaska Native persons with long-term hepatitis B virus infection: 1982-2019.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000658.
    >> Share

  123. LEE CH, Mak LY, Tang EH, Lui DT, et al
    SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
    Hepatology. 2023;78:1569-1580.
    >> Share

    October 2023
  124. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    >> Share

  125. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    >> Share

  126. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    >> Share

  127. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    >> Share

  128. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    >> Share

  129. ELSHEIKH R, Makram AM, Huy NT
    Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000625.
    >> Share

  130. JAGADISAN B, Dhawan A
    Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000622.
    >> Share

    September 2023
  131. CHOLANKERIL G, Vierling JM
    The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough!
    Hepatology. 2023 Sep 18. doi: 10.1097/HEP.0000000000000597.
    >> Share

  132. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    >> Share

  133. GILL US, Peppa D
    Pegylated interferon-alpha for chronic hepatitis B...not ready to be shelved yet! new insights on its role using single-cell transcriptomics.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000560.
    >> Share

    May 2023
  134. TONON M, Balcar L, Semmler G, Calvino V, et al
    Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
    Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
    >> Share

    April 2023
  135. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
    Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
    >> Share

    January 2023
  136. CUNNINGHAM M, Gupta R, Butler M
    Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016